sponsored
PatientsVille.com Logo

PatientsVille

Asmanex Medical Research Studies

Up-to-date List of Asmanex Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Asmanex Medical Research Studies

Rank Status Study
1 Not yet recruiting Intranasal Mometasone in Children With Obstructive Sleep Apnea Due to Adenotonsillar Hypertrophy
Condition: Obstructive Sleep Apnea (Mild, Moderate, Severe) as Per Polysomnography
Interventions: Drug: Mometasone furoate nasal spray;   Drug: Placebo
Outcome Measures: Apnea Hypopnea Index (AHI);   Respiratory Disturbance Index;   Desaturation index;   Respiratory arousal index;   Nadir of arterial oxygen saturation;   Mean arterial oxygen saturation;   Avoidance of surgical treatment for OSA;   Clinical symptom score (based on parent repot of, for example, snoring, witnessed apnea, daytime sleepiness etc.);   Tonsillar size (on an ordinal scale from 0 [not visible] to +4 [tonsils touch])
2 Recruiting A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)
Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg;   Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg;   Drug: Mometasone Furoate MDI 100 mcg;   Drug: Mometasone Furoate MDI 200 mcg;   Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI;   Drug: Prednisone/prednisolone
Outcome Measures: Time-to-first serious asthma outcomes (a composite endpoint defined as asthma-related: hospitalizations, intubations, and deaths);   Time-to-first asthma exacerbation
3 Unknown  Acute Effect of Mometasone Furoate DPI on Beta-adrenergic Airway and Airway Vascular Relaxation in Moderately Severe Asthma
Condition: Asthma
Interventions: Drug: Mometasone furoate;   Drug: placebo
Outcome Measures: airway blood flow changes;   Spirometry (FEV1)
4 Not yet recruiting Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery
Conditions: Sinusitis;   Nasal Polyps;   Asthma
Interventions: Drug: Montelukast;   Drug: mometasone furoate nasal spray
Outcome Measures: Percentage of Participants with Decrease in Nasal symptome Visual Analogue Scale (VAS);   Percentage of Participants with Decrease in nasal endoscopy score (Lund-Kennedy score);   Percentage of Participants with Decrease in sinus CT score (Lund-Mackay, scoring system);   Percentage of Participants with Increase in Asthma Control test (ACT);   Number of Participants with Serious and Non-Serious Adverse Events
5 Recruiting A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)
Condition: Asthma
Interventions: Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg;   Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg;   Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg;   Drug: Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg;   Drug: Placebo Metered Dose Inhaler (MDI);   Drug: Placebo Dry Powder Inhaler (DPI)
Outcome Measures: Change from Baseline in Percent Predicted AM FEV1;   Change from Baseline in AM Peak Expiratory flow (PEF);   Change from Baseline in Standardized Paediatric Asthma Quality of Life Questionnaire Score (PAQLQ(S))
6 Not yet recruiting Demonstrate the Therapeutic Clinical Equivalence of Two Mometasone Nasal Sprays
Conditions: Nasal Obstruction;   Sneezing;   Itching
Intervention: Drug: Mometasone furoate
Outcome Measures: demonstrate the therapeutic clinical equivalence of two mometasone nasal sprays in the relief of the signs and symptoms of perennial allergic rhinitis, in term of changes at week 8 from baseline of Total Nasal Symptom Scores (TNSS).;   Safety monitoring AE, routine laboratory haematology, biochemical tests, urinalysis, assessment of adrenal function to be sure of lack of systemic effect of nasal spray formulation Overall Patient's and Physician's global assessment.
7 Not yet recruiting Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine
Condition: Allergic Rhinitis
Interventions: Drug: Esketamine;   Drug: Mometasone;   Drug: Oxymetazoline
Outcome Measures: Maximum Plasma Concentration (Cmax);   Time to Reach Maximum Concentration (tmax);   Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]);   Elimination Half-Life (t [1/2] Lambda);   Number of participants with adverse events (AEs) and serious adverse events (SAEs)
8 Unknown  A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)
Condition: Mild to Moderate Persistent Allergic Rhinitis
Intervention: Drug: Mometasone furoate
Outcome Measure: Nasal Index Score (NIS) scale that evaluates nasal obstruction, coryza, and sneezing
9 Not yet recruiting Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study.
Condition: Eosinophilic Esophagitis
Intervention: Drug: Mometasone furoate
Outcome Measures: Watson Dysphagia Scale Score (WDS);   The EORTC QLQ-OES18 dysphagia scale, the eating scale and choking item
10 Recruiting Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Condition: Invasive Breast Cancer
Interventions: Other: Eucerin;   Other: Mometasone Furoate 0.1%
Outcome Measures: skin toxicity;   Patient-reported skin toxicities
11 Not yet recruiting Steroids In Eosinophil Negative Asthma
Condition: Asthma
Interventions: Drug: Mometasone 220mcg BID;   Drug: Tiotropium Respimat 5mcg QD;   Drug: Placebo
Outcome Measure: The primary outcome is a composite measure that uses treatment failures, asthma control days, and percent predicted FEV1.
12 Recruiting An Open-label Study to Identify Molecular Markers of Steroid Resistance
Condition: Nasal Polyps
Intervention: Drug: mometasone furoate
Outcome Measures: Steroid Sensitivity in vivo;   Molecular Signature of mRNA;   Steroid sensitivity in vitro
13 Unknown  A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma
Condition: Asthma
Intervention: Drug: Mometasone or Advair
Outcome Measure:
14 Not yet recruiting Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease
Condition: Sickle Cell Disease
Interventions: Drug: Mometasone Furoate;   Drug: Placebo
Outcome Measures: Feasibility;   Change in Effects of inhaled corticosteroids on pulmonary inflammation;   Change in Effects of inhaled corticosteroids vascular injury
15 Recruiting Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Condition: Chronic Rhinosinusitis Without Nasal Polyps
Interventions: Drug: Prednisone;   Drug: Topical mometasone
Outcome Measures: Lund-McKay score from CT scan;   Taskforce symptom inventory;   SNOT-22 Questionnaire;   Medication side-effect and compliance inventory
16 Unknown  Treatment of Phimosis With Topical Steroid Cream -Double-blind, Randomized, Placebo-controlled Study
Condition: Phimosis
Interventions: Drug: Mometasone furoate cream;   Drug: moisturizing cream
Outcome Measure: Retractability of foreskin
17 Recruiting Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea
Conditions: Enuresis;   Obstructive Sleep Apnea;   Sleep Disordered Breathing
Interventions: Device: Bed Alarm;   Drug: Nasonex
Outcome Measures: Degree of improvement in enuresis after a 3 month trial of INS + bed alarm, compared to the bed alarm alone.;   Changes in OSA-18 and PSQ-22 scores after 3 month trial of INS;   Adverse effects related to treatments;   Patient related differences ie obesity, age, sex, and the effect on continence/treatment
18 Unknown  Acute and Chronic Effects of Inhaled Steroids on Pulmonary Function in Persons With Spinal Cord Injury
Condition: Spinal Cord Injury
Intervention: Drug: Mometasone furoate
Outcome Measures: The Acute and Chronic Effects of an Inhaled Corticosteroid on Pulmonary Function;   The Effects of an Inhaled Corticosteroid on Biomarkers of Inflammation in Exhaled Breath Condensate;   The Effect of an Inhaled Corticosteroid on the cellular profile of induced sputum
19 Recruiting An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
Condition: Nasal Polyps
Interventions: Drug: dupilumab SAR231893 (REGN668);   Other: placebo;   Drug: mometasone furoate nasal spray
Outcome Measures: Change from baseline in endoscopic Nasal Polyp Score (NPS);   Change from baseline in NPS in sub-group of co-morbid asthma;   Change from baseline in patient reported symptoms of sinusitis;   Change from baseline in nasal peak inspiratory flow;   Change from baseline in smell test;   Change from baseline in CT scan;   Time to first response in NPS
20 Not yet recruiting Long-Term Safety Evaluation of Dupilumab in Patients With Asthma
Condition: Asthma
Interventions: Drug: dupilumab SAR231893 (REGN668);   Drug: fluticasone propionate and salmeterol;   Drug: budesonide and formoterol;   Drug: mometasone furoate and formoterol
Outcome Measures: Number of participants with adverse events;   Assessment of safety parameters (laboratory data, electrocardiogram and vital signs) - clinically significant changes from baseline;   Forced expiratory volume in one second - clinically significant changes from baseline;   Asthma control questionnaire - clinically significant changes from baseline;   Asthma symptom scores - clinically significant changes from baseline;   Asthma Quality of Life Questionnaire (AQLQS) - clinically significant changes from baseline;   Anti-drug antibodies - changes from baseline;   Biomarkers - changes from baseline

These studies may lead to new treatments and are adding insight into Asmanex etiology and treatment.

A major focus of Asmanex research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Asmanex